Beyond TPMT: Genetic influences on thiopurine drug responses in inflammatory bowel disease

Personalized Medicine

Volumn 5, Issue 3, 2008, Pages 233-248

  Roberts, Rebecca L ^a   Gearry, Richard B ^a,b   Kennedy, Martin A ^a   Barclay, Murray L ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

6 mercaptopurine; 6 methylmercaptopurine; 6 MMP; 6 TGN; 6 thioguanine nucleotides; Azathioprine; Glutathione; GSTM1; IBD; IMPDH; Inflammatory bowel disease; Inosine 5 monophosphate dehydrogenase; Inosine triphosphatase; ITPA; S transferase M1; Thiopurine S methyltransferase; TPMT

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALDEHYDE OXIDASE; ALLOPURINOL; AZATHIOPRINE; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; FOLIC ACID; FUROSEMIDE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; GLUTATHIONE TRANSFERASE M1; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INOSINATE DEHYDROGENASE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; MYCOPHENOLIC ACID; OLSALAZINE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; XANTHINE OXIDASE;

ACUTE GRAFT REJECTION; AMINO ACID SUBSTITUTION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; FLU LIKE SYNDROME; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER HYPERPLASIA; LIVER TOXICITY; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; PANCREATITIS; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; THERAPY RESISTANCE; UNSPECIFIED SIDE EFFECT;

EID: 44949112325     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.3.233     Document Type: Review

References (163)

1. Timmer A, McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. CD000478 (2007).
2. Suarez-Almazor ME, Spooner C, Belseck E: Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst. Rev. CD001461 (2000).
3. Meggitt SJ, Gray JC, Reynolds NJ: Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 367, 839-846 (2006).
4. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P: Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst. Rev. CD001084 (2000).
5. Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining renuission of Crohn's disease. Cochrane Database Syst. Rev. CD000067 (2000).
6. Cuffari C, Theoret Y, Latour S, Seidman G: 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 39, 401-406 (1996).
7. Dubinsky MC, Hassard PV, Seidman EG et al.: An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis. 7, 181-189 (2001).
8. Dubinky MC, Lamothe S, Yang HY et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118, 705-713 (2000).
9. Bonaz B, Boitard J, Marteau P et al.: Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 18, 401-408 (2003).
10. + T lymphocytes. J. Clin. Invest. 111, 1133-1145 (2003).
11. Poppe D, Tiede I, Fritz G et al.: Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176, 640-651 (2006).
12. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA: Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 13, 563-567 (2004).
13. Gearry R, Barclay M, Gardiner S, Zhang M: 6-thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. N. Z. Med. J. 116, U531 (2003).
14. Duley JA, Florin TH: Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 27, 647-654 (2005).
15. Derijks LJ, de Jong DJ, Gilissen LP et al.: 6-thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol. 15, 63-67 (2003).
16. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA: Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am. J. Gastroenterol. 98, 1058-1063 (2003).
17. Herrlinger KR, Kreisel W, Schwab M et al.: 6-thioguanine - efficacy and safety in chronic active Crohn's disease. Aliment. Pharmacol. Ther. 17, 503-508 (2003).
18. Herrlinger KR, Deibert P, Schwab M et al.: Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment. Pharmacol. Ther. 17, 1459-1464 (2003).
19. Dubinsky MC, Vasiliauskas EA, Singh H et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125, 298-303 (2003).
20. Shastri S, Dubinsky MC, Fred Poordad F, Vasiliauskas EA, Geller SA: Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch. Pathol. Lab. Med. 128, 49-53 (2004).
21. Geller SA, Dubinsky MC, Poordad FF et al.: Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am. J. Surg. Pathol. 28, 1204-1211 (2004).
22. Seiderer J, Zech CJ, Reinisch W et al.: A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J. Hepatol. 43, 303-309 (2005).
23. de Boer NK, Zondervan PE, Gilissen LP et al.: Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver Dis. 40(2), 108-113 (2008).
24. Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin. Chim. Acta. 85, 323-333 (1978).
25. Wainshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980).
26. Lennard L, Van Loon JA, Weinshilboum RM: Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149-154 (1989).
27. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV: Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM 95, 439-444 (2002).
28. Gardiner SJ, Begg EJ: Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet. Genomics 15, 365-369 (2005).
29. Haga SB, Thummel KE, Burke W: Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet. Genomics 16, 847-854 (2006).
30. Colombel JF, Ferrari N, Debuysere H et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118, 1025-1030 (2000).
31. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34, 1081-1105 (1993).
32. Ansari A, Hassan C, Duley J et al.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 1743-1750 (2002).
33. Kurzawski M, Dziewanowski K, Gawronska-Szklarz B, Domanski L, Drozdzik M: The impact of thiopurine S-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Ther. Drug Monit. 27, 435-441 (2005).
34. Gearry RB, Barclay ML, Burt MJ et al.: Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in Patients with inflammatory bowel disease. Aliment. Pharmacal. Ther. 18, 395-400 (2003).
35. Schwab M, Schaffeler E, Marx C et al.: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12, 429-436 (2002).
36. Kader HA, Wenner WJ Jr, Telega GW, Maller ES, Baldassano RN: Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J. Clin. Gastroenterol. 30, 409-413 (2000).
37. Lowry PW, Franklin CL, Weaver AL et al.: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49, 665-670 (2001).
38. Campbell S, Kingstone K, Ghosh S: Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment. Pbarmacol. Ther. 16, 389-398 (2002).
39. Black AJ, McLeod HL, Capell HA et al.: Thiopurine methyltransferase genotype predicts therapy-limitting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998).
40. Marinaki AM Ansari A, Duley JA et al.: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14, 181-187 (2004).
41. Stocco G, Martelossi S, Barabino A et al.: Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13, 57-64 (2007).
42. Arenas M, Simpson G, Lewis CM et al.: Genetic variation in the MTHFRgene influences thiopurine methyltransferase activity. Clin. Chem. 51, 2371-2374 (2005).
43. Roberts RL, Gearry RB, Barclay ML, Kennedy MA: IMPDH1 promoter mutations in a patient exhibiting azathioprin. resistance. Pharmacogenomics J. 7, 312-317 (2007).
44. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM: Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2, 148-159 (1992).
45. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Acad. Sci. USA 92, 949-953 (1995).
46. Lee D, Szumlanski C, Houtman J et al.: Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab. Dispos. 23, 398-405 (1995).
47. Woodson LC, Dunnette JH, Weinshilboum RM: Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol. Exp. Ther. 222, 174-181 (1982).
48. McLeod HL, Krynetski EY. Walimas JA, Evans WE: Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 5, 281-286 (1995).
49. Fessing MY, Krynetski EY, Zambetti GP, Evans WE: Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. Eur. J. Biochem. 256, 510-517 (1998).
50. Xin HW, Fischer C, Schwab M, Klotz U: Thiopurine S-methyltransferase as a target for drug interactions. Eur. J. Clin. Pharmacol. 61, 395-398 (2005).
51. Lewis LD, Benin A, Szumlanski CL et al.: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin. Pharmacol. Ther. 62, 464-475 (1997).
52. Szumlanski CL, Weinshilboum RM: Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 39, 456-459 (1995).
53. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandburn WJ: Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 116, 1505-1506 (1999).
54. Xin H, Fischer C, Schwab M, Klotz U: Effects of aminosalicylates on thiopurine S-methyltransferase activity; an ex vivostudy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 21, 1105-1109 (2005).
55. de Boer NK, Wong DR, Jharap B et al.: Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am. J. Gastroenterol. 102, 2747-2753 (2007).
56. Gilissen LP, Bierau J, Derijks LJ et al.: The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment. Pharmacol. Ther. 22, 605-611 (2005).
57. Dilger K, Schaeffeler E, Lukas M et al.: Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther. Drug Monit. 29, 1-5 (2007).
58. Brouwer C, De Abreu RA, Keizer-Garritsen JJ et al.: Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects. Eur. J. Cancer. 41, 613-623 (2005).
59. Vuchetich JP, Weinshilboum RM, Price RA: Segregation analysis of human red blood cell thiopurine methyltransferase activity. Genet. Epidemiol. 12, 1-11 (1995).
60. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM: Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet. Genomics 15, 801-815(2005).
61. Szumlanski C, Otterness D, Her C et al.: Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15, 17-30 (1996).
62. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL: Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet. 8, 367-370 (1999).
63. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evańs WE: Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. 8, 371-376 (1999).
64. Haglund S, Lindqvist M, Almer S, Peterson C, Taipalensuu J: Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease. Clin. Chem. 50, 288-295 (2004).
65. Hamdy SI, Hiratsuka M, Narahara K et al.: Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br. J. Clin. Pharmacol. 55, 560-569 (2003).
66. Larovere LE, de Kremer RD, Lambooy LH. De Abreu RA: Genetic polymorphism of thiopurine S-methyltransferase in Argentina. Ann. Clin. Biochem. 40, 388-393 (2003).
67. Schaeffeler E, Fischer C, Brockmeier D et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407-417 (2004).
68. Collie-Duguid ES, Pritchard SC, Powrie RH et al.: The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9, 37-42 (1999).
69. Kham SK, Tan PL, Tay AH, Heng CK, Yeoh AE, Quah TC: Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 24, 353-359 (2002).
70. Kumagai K, Hiyama K, Ishioka S et al.: Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 11, 275-278 (2001).
71. Chang JG, Lee LS,Chen CM et al.: Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics 12, 191-195 (2002).
72. McLeod HL, Pritchard SC, Githanga'a J et al.: Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9, 773-776 (1999).
73. Alves S, Rocha J, Amorim A, Prata MJ: Tracing the origin of the most common thiopurine methyltransferase (TPMT) variants: preliminary data from the patterns of haplotypic association with two CA repeats. Ann. Hum. Genet. 68, 313-323 (2004).
74. Oliveira E, Quental S, Alves S, Amorim A, Prata MJ: Do the distribution patterns of polymorphisms at the thiopurine S-methyltansferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur. J. Clin. Pharmacol. 63, 703-706 (2007).
75. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM: Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J. Clin. Invest. 101, 1036-1044 (1998).
76. Otterness, D, Szumlanski C, Lennard L et al.: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62, 60-73 (1997).
77. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B et al.: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J. Pharmacol. 125, 879-887 (1998).
78. Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M: Three novel thiopurine S-methyltransferase allelic variants ( TPMT*20, *21, *24)- association with decreased enzyme function. Hum. Mutat. 27, 976 (2006).
79. Schaeffeler E, Stanulla M, Greil J et al.: A novel TPMT missense mutation associated with TPMT deficiency in a 5- year-old boy with ALL. Lukemia 17, 1422-1424 (2003).
80. Hamdan-Khalil R, Allorge D, Lo-Guidice JM et al.: In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochem. Biophys. Res. Commun. 309, 1005-1010 (2003).
81. Lindqvist M, Haglund S, Almer S et al.: Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 14, 261-265 (2004).
82. Hamdan-Khalil R, Gala JL, Allorge D et al.: Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem. Pharmacol. 69, 525-529 (2005).
83. Lindqvist M, Skoglund K, Karlgren A et al.: Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23. Pharmacogenet. Genomics 17, 891-895 (2007).
84. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Aivarado M, Weinshilboum RM: Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl Acad. Sci. USA 102, 9394-9399 (2005).
85. Spire-Vayron de la Moureyre C, Debuysere H, Fazio F et al.: Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9, 189-198 (1999).
86. Marinaki AM, Arenas M, Khan ZH et al.: Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 13, 97-105 (2003).
87. Alves S, Amorim A, Ferreira F, Prata MJ: Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin. Pharmacol Ther. 70, 165-174 (2001).
88. Wang L, Weinshilboum R: Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25, 1629-1638 (2006).
89. Yan L, Zhang S, Eiff B et al.: Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin. Pharmacol. Ther. 68, 210-219 (2000).
90. Roberts RL, Gearry RB, Bland ML et al.: Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet. Genomics 18(5), 434-438 (2008).
91. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274, 516-520 (1995).
92. Ingelman-Sundberg M: Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab. Rev. 31, 449-459 (1999).
93. Rao Y, Hoffmann E, Zia M et al.: Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58, 747-755 (2000).
94. Hildebrandt MA, Salavaggione OE, Martin YN et al.: Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem. Biophys. Res. Commun. 321, 870-878 (2004).
95. Iafrate AJ, Feuk L, Rivera MN et al.: Detection of large-scale variation in the human genome. Nat. Genet. 36, 949-951 (2004).
96. Arenas M, Simpson G, Lewis CM et al.: Genetic variation in the MTHFR gene influences thiopurie methyltransferase activity. Clin. Chem. 51, 2371-2374 (2005).
97. Tai HL, Fessing MY, Bonten EJ et al.: Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMTB or TPMT*3C. Pharmacogenetics 9, 641-650 (1999).
98. Scheuermann TH, Keeler C, Hodsdon ME: Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone. Biochemistry 43, 12198-12209 (2004).
99. Fux R, Kloor D, Hermes M et al.: Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers. Am. J. Physiol. Renal Physiol. 289, F786-F792 (2005).
100. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, Lentz SR: Effect of mthfr genotype on diet induced hyperhomocysteinemia and vascular function in mice. Blood 103, 2624-2629 (2004).
101. Al-Gazali LI, Padmanabhan R, Melnyk S et al.: Abnormal folate metabolism and genetic polymorphism of the folate pathway in a child with Down syndrome and neural tube defect. Am. J. Med. Genet. 103, 128-132 (2001).
102. Vanderheiden BS: Human erythrocyte 'ITPase': an ITP pyrophosphohydrolase. Biochim. Biophys. Acta 215, 555-558 (1970).
103. Zachara B, Lewandowski J: Isolation and identification of inosine triphosphate from human erythrocytes. Biochim. Biophys. Acta 353, 253-259 (1974).
104. Vanderheiden BS: Purification and properties of human erythrocyte inosine triphosphate pyrophosphohydrolase. J. Cell Physiol. 98, 41-47 (1979).
105. Vanderheiden BS: Genetic studies of human erythrocyte inosine triphosphatase. Biochem. Genet. 3, 289-297 (1969).
106. Fraser JH, Meyers H, Henderson JF, Brox LW, McCoy EE: Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin. Biochem. 8, 43-364 (1975).
107. Holmes SL, Turner BM, Hirschhorn K: Human inosine triphosphatase: catalytic properties and population studies. Clin. Chim. Acta. 97, 143-153 (1979).
108. Soder C, Henderson JF. Zombe G, McCoy EE, Verhoef V, Morris AJ: Relationships between nucleoside triphosphate pyrophosphohydrolase activity and inosine triphosphate accumulation in human erythrocytes. Can. J. Biochem. 54, 843-847 (1976).
109. van Waeg G, Niklasson F, Ericson A, de Verdier CH: Purine metabolism in normal and ITP-pyrophosphohydrolase- deficient human erythrocytes. Clin. Chim. Acta. 171, 279-292 (1988).
110. Cao H, Hegele RA: DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J. Hum. Genet. 47, 620-622 (2002).
111. Sumi S, Marinaki AM, Arenas M et al.: Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111, 360-367 (2002).
112. Heuer T, Oellerich M, Armstrong VW, von Ahsen N: Rapid detection of ITPA 94C>A and IVS2 + 21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A>C polymorphism on splicing efficiency. Clin. Chem. 50, 2182-2184 (2004).
113. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A: The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim. Biophys. Acta 1772, 96-102 (2007).
114. Maeda T, Sumi S, Ueta A et al.: Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol. Genet. Metab. 85, 271-279 (2005).
115. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N: Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin. Chem. 52, 240-247 (2006).
116. Atanasova S, Shipkova M, Svinarov D et al.: Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther. Drug Monit. 29, 6-10 (2007).
117. Gearry RB, Roberts RL, Barclay ML, Kennedy MA: Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14, 779-781 (2004).
118. van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ: ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 54, 1664 (2005).
119. Zelinkova Z, Derijks IJ, Stokkers PC et al.: Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 4, 44-49 (2006).
120. Allorge D, Harridan R, Broly F, Libersa C, Colombal JF: ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54, 565 (2005).
121. De Ridder L, Van Dieren JM, Van Deventer HJ et al.: Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment Pharmacol. Ther. 23, 1137-1141 (2006),
122. Breen DP, Marinaki AM, Arenas M, Hayes PC: Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 11, 826-833 (2005).
123. von Ahsen N, Armstrong VW, Behrens C et al.: Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathlioprine therapy in a prospective Crohn disease study. Clin. Chem. 51, 2282-2288 (2005).
124. Elion GB: The purine path to chemotherapy. Science 244, 41-47 (1989).
125. Eklund BI, Moberg M, Bergquist J, Mannervik B: Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol. Pharmacol. 70, 747-754 (2006).
126. Hobara N, Watanabe A: Impaired metabolism of azathioprine in carbon tetrachloride-injured rats. Hepatogastroenterology 28, 192-194 (1981).
127. Kaplowitz N: Enzymatic thiolysis of azathioprine in vitro. Biochem. Pharmacol. 25, 2421-2426 (1976).
128. Kaplowitz N, Kuhlenkamp, J: Inhibition of hepatic metabolism of azathioprine in vivo. Gastroenterology 74, 90-92, (1978).
129. Cara CJ, Pena AS, Sans M et al.: Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med. Sci. Monit. 10, RA247-RA254 (2004).
130. McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR: Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology, 122, 838-839 (2002).
131. Board PG: Biochemical genetics of glutatitione-S-transferase in man. Am. J. Hum. Genet. 33, 36-43 (1981).
132. Guy CA, Hoogendoorn B, Smith SK, Coleman S, O'Donovan MC, Buckland PR: Promoter polymorphisms in glutathione-S-transferase genes affect transcription. Pharmacogenetics 14, 45-51 (2004).
133. Morel F, Rauch C, Coles B, Le Ferrec E, Guillouzo A: The human glutathione transferase α locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics 12, 277-286 (2002).
134. Tetlow N, Liu D, Board P: Polymorphism of human α class glutathione transferases. Pharmacogenetics 11, 609-617 (2001).
135. Collart FR, Huberman E: Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J. Biol. Chem. 263, 15769-15772 (1988).
136. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber, G, Suzuki K: Two distinct cDNAs for human IMP dehydrogenase. J. Biol. Chem. 265, 5292-5295 (1990).
137. Carr SF, Papp E, Wu JC, Natsumeda Y: Characterization of human Type I and Type II IMP dehydrogenases. J. Biol. Chem. 268, 27286-27290 (1993).
138. Hager PW, Collart FR, Huberman E, Mitchell BS: Recombinant human inosine monophosphate dehydrogenase type I and type II protein. Purification and characterization of inhibitor binding. Biochem. Pharmacol. 49, 1323-1329 (1995).
139. Gu JJ, Tolin AK, Jain J, Huang H, Santiago L, Mitchell BS: Targeted disruption of the inosine 5′-monophosphate dehydrogenase type I gene in mice. Mol. Cell Biol. 23, 6702-6712 (2003).
140. Gu JJ, Stegmann S, Gathy K et al.: Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J. Clim. Invest. 106, 599-606 (2000).
141. Gu JJ, Kaiser-Rogers K, Rao K, Mitchell BS: Assignment of the human type I IMP dehydrogenase gene (IMPDH1) to chromosome 7q31.3-q32. Genomics 24, 179-181 (1994).
142. Kost-Alimova MV, Glesne DA, Huberman E, Zelenin AV: Assignment1 of inosine'-monophosphate dehydrogenase type 2 (IMPDH2) to human chromosome band 3p21.2 by in situ hybridization. Cytogenet. Cell Genet. 82, 145-146 (1998).
143. Senda M, Natsumeda Y: Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). Life Sci. 54, 1917-1926 (1994).
144. Gu JJ, Spychala J, Mitchell BS: Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. J. Biol. Chem. 272, 4458-4466 (1997).
145. Bowne SJ, Sullivan LS, Blanton SH et al.: Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11, 559-568 (2002).
146. Bowne SJ, Sullivan LS, Mortimer SE et al.: Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest. Ophthalmol Vis. Sci. 47, 34-42 (2006),
147. Wang J, Zeevi A, Webber S et al.: A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet. Genomics 17, 283-290 (2007).
148. Wang J, Yang JW, Zeevi A et al.: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther. 83(5), 711-717 (2008).
149. Haglund S, Taipalensuu J, Peterson C, Almer S: IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol. 65(1), 69-77 (2008).
150. Nakamura J, Straub K, Wu J, Lou L: The glutamine hydrolysis function of human GMP synthetase. Identification of an essential active site cysteine. J. Biol. Chem. 270, 23450-23455 (1995).
151. Tesmer JJ, Klem TJ, Deras ML, Davisson VJ, Smith JL: The crystal structure of GMP synthetase reveals a novel catalytic triad and is a structural paradigm for two enzyme families. Nat. Struct. Biol. 3, 74-86 (1996).
152. Lennard L: The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329-339 (1992).
153. Chocair P, Duley J, Simmonds HA et al.: Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen, Lancet 342, 83-84 (1993).
154. Sparrow MP, Hande SA, Friedman S et al.: Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 22, 441-446 (2005).
155. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB: Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 5, 209-214 (2007).
156. Wong DR, Derijks LJ, den Dulk MO, Gemmeke EH, Hooymans PM: The role of xanthine oxidase in thiopurine metabolism: a case report. Ther. Drug Monit. 29, 845-848 (2007).
157. Kudo M, Moteki T, Sasaki T et al.: Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet. Genomics 18, 243-251 (2008).
158. Wessels JA, van der Kooij SM, le Cessie S et al.: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56, 1765-1775 (2007).
159. Rashidi MR, Beedham C, Smith JS, Davaran S: In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab. Pharmacokinet. 22, 299-306 (2007).
160. Seki T, Tanaka T, Nakamura Y: Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J. Hum. Genet. 45, 299-302 (2000).
161. Alves S, Ferreira F, Prata MJ, Amorim A: Characterization of three new VNTR alleles in the promoter region of the TPMT gene. Hum. Mutat. 15, 121 (2000).
162. Alves S, Amorim A, Prata MJ: Evolution of a VNTR located within the promoter region of the thiopurine methyltransferase gene: inferences from population and sequence data. Hum. Genet. 111, 172-178 (2002).
163. Gearry RB, Barclay ML: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20, 1149-1157 (2005).